Panorama Test Outsource Natera at Chughtai Lab

Panorama Test Outsource Natera at Chughtai Lab

The Panorama Non-Invasive Prenatal Test (NIPT) by Natera, offered as an outsourced diagnostic service at Chughtai Lab in Pakistan, represents a revolutionary advancement in prenatal care. This highly sophisticated screening test analyzes cell-free DNA (cfDNA) circulating in the maternal bloodstream to evaluate the genetic health of a developing fetus. Unlike traditional prenatal screening methods, which rely on maternal serum biomarkers and ultrasound measurements, the Panorama test directly sequences the genetic material originating from the placenta. This allows for the early, safe, and highly accurate detection of common chromosomal abnormalities, providing expectant parents and healthcare providers with critical clinical insights as early as the ninth week of pregnancy.

Chughtai Lab, a premier diagnostic network in Pakistan with a legacy of clinical excellence, partners with Natera, a global leader in genetic testing based in the United States, to make this advanced screening accessible to patients across the country. Through this partnership, maternal blood samples are collected at Chughtai Lab locations in Lahore, Karachi, Islamabad, and other major cities under strict quality control protocols. The specimens are then securely transported to Natera's state-of-the-art laboratory in the USA for high-throughput sequencing and bioinformatic analysis. By leveraging Natera's proprietary Single Nucleotide Polymorphism (SNP) technology, the Panorama test offers unparalleled accuracy in distinguishing maternal DNA from fetal DNA, minimizing false positives and false negatives.

The clinical importance of the Panorama NIPT lies in its ability to screen for major chromosomal aneuploidies, including Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome), alongside sex chromosome anomalies and select microdeletion syndromes. Because the test is completely non-invasive, requiring only a simple maternal blood draw, it poses absolutely zero risk of miscarriage, unlike invasive diagnostic procedures such as amniocentesis or chorionic villus sampling (CVS). This makes it an invaluable first-line screening tool that empowers families with reliable information, guides clinical management, and helps avoid unnecessary invasive testing for low-risk pregnancies.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure specimen integrity and accurate results for the Panorama NIPT at Chughtai Lab. Patients should observe the following guidelines:

• Gestational Age Verification: The test must be performed only after completing at least 9 weeks of gestation. An early dating ultrasound is highly recommended prior to sample collection to confirm accurate gestational age and determine if it is a singleton or twin pregnancy.
• No Fasting Required: There is no need to fast before the blood draw. Patients are encouraged to eat normally and stay well-hydrated, as hydration can make venipuncture easier.
• Medication Review: Inform the healthcare provider and the laboratory staff about any ongoing medications, particularly blood thinners or low-molecular-weight heparin, as these can occasionally affect the fetal fraction in the maternal blood.
• Clinical Documentation: Patients must present a valid prescription from their obstetrician, along with a completed Natera consent and clinical requisition form detailing maternal age, gestational age, and pregnancy history.
• Pre-test Counseling: It is highly recommended to undergo genetic counseling to understand the scope, limitations, and potential implications of the screening results.

During the Procedure

The sample collection process for the outsourced Panorama test at Chughtai Lab is streamlined to prioritize patient comfort and specimen safety:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair. The phlebotomist verifies the patient's identity and cross-checks the clinical requisition forms.
• Venipuncture: A highly trained phlebotomist cleanses the venipuncture site (usually the antecubital fossa of the arm) with an antiseptic solution. A small needle is inserted to draw two tubes of maternal blood into specialized Streck tubes designed to preserve cell-free DNA.
• Specimen Handling: The collected blood tubes are immediately inverted gently to mix the blood with the preservative. The tubes are labeled with unique barcodes matching the patient's registration details to prevent any identification errors.
• Cold Chain Maintenance: The specimens are packaged in specialized temperature-controlled kits provided by Natera. Chughtai Lab maintains a strict cold chain and handles all logistics, including customs clearance and international air transport, to ensure the sample reaches Natera's laboratory in the USA in optimal condition.
• Duration and Safety: The blood draw itself takes less than five minutes. It is a safe, routine procedure with minimal discomfort, carrying only a slight risk of minor bruising at the needle insertion site.

When is a Panorama Test Performed?

Advanced Maternal Age

Obstetricians frequently recommend the Panorama NIPT for pregnant individuals who will be 35 years of age or older at the time of delivery. As maternal age increases, the risk of chromosomal nondisjunction during meiosis rises significantly, leading to a higher incidence of fetal aneuploidies such as Down syndrome. The Panorama test provides these patients with a highly sensitive, risk-free screening option early in pregnancy, allowing them to make informed decisions without exposing the fetus to the procedural risks associated with invasive diagnostic testing.

Abnormal Maternal Serum Screening Results

When traditional first-trimester combined screening (nuchal translucency ultrasound and biochemical markers) or second-trimester quadruple screening yields abnormal or borderline results, the Panorama test is often utilized as a highly accurate secondary screen. Because of its superior sensitivity and specificity, the Panorama test can clarify ambiguous results, significantly reducing parental anxiety and helping to determine whether invasive diagnostic procedures like amniocentesis are truly warranted.

Ultrasound Abnormalities in Fetal Development

If a routine prenatal ultrasound reveals structural anomalies or soft markers associated with chromosomal disorders—such as an increased nuchal translucency, absent nasal bone, or cardiac defects—physicians will recommend advanced genetic screening. The Panorama test helps identify if these physical anomalies are linked to specific chromosomal aneuploidies or microdeletions, providing crucial diagnostic context that guides subsequent maternal-fetal medical management and delivery planning.

Family History of Genetic Disorders or Microdeletions

A strong family history of genetic abnormalities, a previous pregnancy affected by a chromosomal aneuploidy, or a parental carrier status for specific microdeletions are strong indications for the Panorama test. Unlike standard NIPTs, the Panorama panel can screen for microdeletions, such as 22q11.2 deletion syndrome (DiGeorge syndrome), which occur independently of maternal age. Identifying these conditions early allows healthcare providers to prepare specialized pediatric care immediately after birth.

Parental Anxiety and Desire for Early Reassurance

Many expectant parents choose to undergo the Panorama test simply for peace of mind. Because the test can be performed as early as 9 weeks of gestation and offers a detection rate of over 99% for Down syndrome, it provides early reassurance regarding the genetic health of the baby. This early insight helps alleviate anxiety, allowing families to focus on a positive pregnancy experience with a clear understanding of their genetic risks.

What Does a Panorama Test Detect?

The Panorama test utilizes advanced SNP-based next-generation sequencing to detect a wide array of genetic conditions and clinical parameters, including:

• Trisomy 21: Down syndrome, characterized by intellectual disability and congenital heart defects.
• Trisomy 18: Edwards syndrome, associated with severe developmental delays and structural abnormalities.
• Trisomy 13: Patau syndrome, a severe chromosomal condition linked to multiple organ defects.
• Monosomy X: Turner syndrome, affecting female individuals and causing growth and cardiac issues.
• Klinefelter Syndrome (XXY): A sex chromosome aneuploidy affecting male physical and cognitive development.
• Triple X Syndrome (XXX): A sex chromosome variation in females, often presenting with mild or no symptoms.
• Jacobs Syndrome (XYY): A sex chromosome variation in males, sometimes associated with mild learning difficulties.
• Triploidy: A rare condition where the fetus has three complete sets of chromosomes, often leading to early pregnancy loss.
• 22q11.2 Deletion Syndrome: Also known as DiGeorge syndrome, causing heart defects, immune issues, and developmental delays.
• 1p36 Deletion Syndrome: A microdeletion syndrome associated with severe intellectual disability and physical anomalies.
• Angelman Syndrome: A genetic disorder causing severe developmental delays, speech impairment, and neurological issues.
• Prader-Willi Syndrome: A microdeletion syndrome characterized by hypotonia, feeding difficulties, and cognitive impairment.
• Cri-du-chat Syndrome: A chromosomal deletion causing a high-pitched cry, microcephaly, and intellectual disability.
• Fetal Sex: Accurate determination of the biological sex of the fetus (where legally and clinically appropriate).
• Twin Zygosity: Distinguishes between identical (monozygotic) and fraternal (dizygotic) twin pregnancies.
• Individual Fetal Fraction: Measures the exact percentage of fetal cell-free DNA in the maternal blood for each twin.
• Maternal Triploidy: Identifies maternal genetic variations that could affect the pregnancy or test interpretation.
• Vanishing Twin Presence: Detects genetic material from a twin that demised early in pregnancy, preventing false positives.
• Placental Mosaicism: Identifies discrepancies where abnormal cells are confined to the placenta.
• Fetal Fraction Threshold: Ensures the sample contains sufficient fetal DNA (typically above 2.8% to 4%) to guarantee a reliable result.

Turnaround Time and Report Access at Chughtai Lab

Because the Panorama NIPT is an outsourced test requiring international transport and highly specialized molecular sequencing at Natera's laboratory in the United States, the turnaround time is longer than standard local laboratory tests. Typically, the comprehensive genetic report is completed and delivered within 10 to 14 working days from the date of sample collection at Chughtai Lab.

Chughtai Lab ensures seamless access to these critical results through multiple digital channels. Once the report is finalized and verified by Natera's clinical geneticists and reviewed by Chughtai Lab's pathology experts, patients receive an automated SMS notification. The report can be downloaded securely via the Chughtai Lab official website portal or the Chughtai Healthcare mobile application. Additionally, patients can collect a printed copy of their report from any convenient Chughtai Lab diagnostic center across Pakistan.

Panorama Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Trisomy 21 (Down Syndrome)	Low Risk (probability of occurrence is extremely low)	High Risk (suggestive of fetal Trisomy 21; requires diagnostic confirmation)
Trisomy 18 (Edwards Syndrome)	Low Risk (probability of occurrence is extremely low)	High Risk (suggestive of fetal Trisomy 18; high clinical correlation)
Trisomy 13 (Patau Syndrome)	Low Risk (probability of occurrence is extremely low)	High Risk (suggestive of fetal Trisomy 13; associated with severe anomalies)
Sex Chromosome Aneuploidies	Normal sex chromosome complement (XX or XY)	Aneuploidy detected (e.g., Monosomy X, XXY, XXX, XYY)
Triploidy	Diploid chromosome complement (normal 46 chromosomes)	Triploid detected (69 chromosomes; high risk of pregnancy complications)
22q11.2 Deletion Syndrome	No deletion detected at the 22q11.2 locus	High Risk for 22q11.2 microdeletion (DiGeorge syndrome)
Fetal Fraction	Sufficient fetal cfDNA detected (typically > 2.8% to 4%)	Low Fetal Fraction (insufficient DNA for analysis; may require a redraw)
Twin Zygosity	Identified as monozygotic or dizygotic (if applicable)	Discordant twin findings or vanishing twin detected

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Panorama Test?

• Official Partnership with Natera USA: Direct collaboration ensures your sample is processed using genuine, world-class SNP technology at Natera's accredited laboratory.
• Strict Cold Chain Logistics: Chughtai Lab maintains rigorous temperature-controlled transport protocols to preserve maternal blood samples during international transit.
• Convenient Home Sample Collection: Patients can schedule a professional phlebotomist to collect the blood sample in the comfort and privacy of their homes.
• Highly Trained Phlebotomists: Specialized staff experienced in maternal blood collection, ensuring a gentle and efficient venipuncture process.
• Seamless Digital Report Access: Retrieve your genetic reports instantly through the user-friendly Chughtai Lab mobile app or online portal.
• Nationwide Network: Accessible sample collection centers across all major cities of Pakistan, including Lahore, Karachi, and Islamabad.
• Comprehensive Clinical Support: Chughtai Lab's dedicated customer care and medical teams are available to guide patients through the registration and testing process.
• Commitment to Quality Diagnostics: Adherence to international standards of laboratory practice, ensuring reliability, confidentiality, and peace of mind for expectant families.